ライフサイエンスコーパス: tachycardia

1 ed cardiac arrest, and sustained ventricular tachycardia).

2 3, couplets; and 4, nonsustained ventricular tachycardia).

3 esented to the cardiology service with sinus tachycardia.

4 th catecholaminergic polymorphic ventricular tachycardia.

5 topic activity in patients with focal atrial tachycardia.

6 AV block, heart failure and supraventricular tachycardia.

7 t and resulted in less inducible ventricular tachycardia.

8 tial examination revealed BP 90/60 mm Hg and tachycardia.

9 in catecholaminergic polymorphic ventricular tachycardia.

10 ntricular fibrillation/pulseless ventricular tachycardia.

11 ion), there were 680 episodes of ventricular tachycardia.

12 for atrial fibrillation or supraventricular tachycardia.

13 failure patients with sustained ventricular tachycardia.

14 tricular fibrillation /pulseless ventricular tachycardia.

15 ue to serious adverse events of vomiting and tachycardia.

16 ise in the management of inappropriate sinus tachycardia.

17 ined history of 6577 episodes of ventricular tachycardia.

18 ure increases as a function of the degree of tachycardia.

19 >30 seconds of AF, atrial flutter, or atrial tachycardia.

20 nnel block alone did not prevent ventricular tachycardia.

21 nd catecholaminergic polymorphic ventricular tachycardia.

22 ense, prolonged cortical arousals and marked tachycardia.

23 c arrest and three non-sustained ventricular tachycardia.

24 length TdP, and slow monomorphic ventricular tachycardia.

25 the critical element of perimitral reentrant tachycardias.

26 drove 30% (7/23) of our postablation atrial tachycardias.

27 tion greater than 7 days (2.78 [1.40-5.54]), tachycardia (2.99 [1.48-6.06]), hypoxemia (4.40 [2.03-9.

28 3%), liver abscesses (3%), paroxysmal atrial tachycardia (3%), thoracic pain (3%), upper gastrointest

29 psis (5.1%) in the ablation group and atrial tachycardia (3.9%) in the medication group.

30 hese, 177 (28.8%) had idiopathic ventricular tachycardia, 408 (66.5%) had symptomatic PVCs, and 29 (4

31 lity to induction of polymorphic ventricular tachycardia (60 vs. 24% in Kcne5(+/0) mice), and 10% sho

32 ted with subjective fever or chills; 97% had tachycardia, 80% had gastrointestinal symptoms, 60% had

33 trial fibrillation (28.8%), and focal atrial tachycardia (9.5%).

34 atients who underwent epicardial ventricular tachycardia ablation and Lariat left atrial appendage ex

35 al procedures such as epicardial ventricular tachycardia ablation and Lariat left atrial appendage li

36 es in both Lariat and epicardial ventricular tachycardia ablation groups.

37 Acute procedural success of atrial tachycardia ablation in congenital heart patients was no

38 Ventricular tachycardia ablation is often limited by insufficient le

39 ergoing epicardial access during ventricular tachycardia ablation or Lariat procedure is associated w

40 ter shows promise for decreasing ventricular tachycardia ablation procedure time and improving outcom

41 This may improve the efficacy of ventricular tachycardia ablation procedures while reducing the numbe

42 lves, who underwent scar-related ventricular tachycardia ablation, were analyzed to correlate the tim

43 ss was freedom from AF/atrial flutter/atrial tachycardia absent new/increased dosage of previously fa

44 tion of patients with freedom from AF/atrial tachycardia after a single procedure was 49.2% (91/185)

45 substrate may lead to recurrent ventricular tachycardia after catheter ablation.

46 ent incidence of post-transplant ventricular tachycardia, although further large animal model studies

47 patients with noninfarct related ventricular tachycardia and 4 patients with infarct-related ventricu

48 ardiac arrhythmias (i.e. inappropriate sinus tachycardia and bradycardia, asystole, and atrioventricu

49 e, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome.

50 ntricular tachyarrhythmias (i.e. ventricular tachycardia and fibrillation (VT, VF)) on admission at o

51 th catecholaminergic polymorphic ventricular tachycardia and his father with left ventricular noncomp

52 terial pressure in addition to resolution of tachycardia and improved peripheral perfusion are often

53 ins exhibited a significant post-respiratory tachycardia and increased SV.

54 Ventricular tachycardia and premature ventricular complexes (PVCs) m

55 a and AV block, but the atropine-insensitive tachycardia and PVCs were abolished by the beta(1) -adre

56 not associated with typical signs including tachycardia and pyrexia.

57 on were seen in 6 patients, with ventricular tachycardia and/or cardiac arrest in 3 patients.

58 Fifty patients (60%) had ventricular tachycardia and/or ventricular fibrillation alternating

59 Multivariable analysis retained ventricular tachycardia and/or ventricular fibrillation episodes alt

60 Ventricular tachycardia and/or ventricular fibrillation episodes alt

61 ythm and 33 (40%) had refractory ventricular tachycardia and/or ventricular fibrillation.

62 c VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing episodes.

63 ost-cardiotomy shock, refractory ventricular tachycardia, and acute management of complications of in

64 2, the patient developed afebrile tachypnea, tachycardia, and an increasing oxygen requirement.

65 trial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block and inversely co

66 trial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block), which carries

67 entrant tachycardia, monomorphic ventricular tachycardia, and Brugada syndrome.

68 urthermore, adenosine prevented weight loss, tachycardia, and compromised lung function in E. coli-ex

69 to progressive deterioration in bodyweight, tachycardia, and muscle wasting, predisposing affected i

70 e arrhythmic beats that initiate ventricular tachycardia, and regarding optimal therapeutic approache

71 te catecholaminergic polymorphic ventricular tachycardia are classified ambiguously as variants of un

72 findings suggest that cortical feedback and tachycardia are integrated responses of the swallow moto

73 Most recurrent ventricular tachycardias are localized to regions of prior defined s

74 tachycardia, atrioventricular node reentrant tachycardia) are significant predominantly because of th

75 n could improve the treatment of ventricular tachycardia arising from mid myocardial or epicardial su

76 reedom from atrial fibrillation, flutter, or tachycardia at 12 months was observed in 84 of 148 (56.5

77 rial fibrillation, atrial flutter, or atrial tachycardia at 12 months.

78 likelihood of remaining free of AF or atrial tachycardia at 6 and 12 months.

79 we assess the efficacy of optogenetic atrial tachycardia (AT) termination in human hearts using a str

80 ive approach to activation mapping of atrial tachycardia (AT) that avoids electrogram annotation.

81 ibility of optogenetic termination of atrial tachycardia (AT), comparing two different illumination s

82 the last decade, severe and refractory sinus tachycardia, atrial fibrillation, and ventricular tachyc

83 Tachycardias, atrial fibrillation, and premature ventric

84 come was symptomatic recurrence of AF/atrial tachycardia/atrial flutter lasting >30 seconds, determin

85 tion, 82% remained AF-free and 74% AF/atrial tachycardia/atrial flutter-free during follow-up on or o

86 remained AF-free and 66% remained AF/atrial tachycardia/atrial flutter-free on or off AADs (antiarrh

87 , atrial fibrillation/atrial flutter, atrial tachycardia, atrioventricular nodal reentrant tachycardi

88 nduced arrhythmias (bradyarrhythmias, atrial tachycardia, atrioventricular node reentrant tachycardia

89 erentiation of atrioventricular node reentry tachycardia (AVNRT) and atrioventricular reentry tachyca

90 Atrioventricular nodal reentrant tachycardia (AVNRT) is considered a sporadic disease occ

91 ycardia (AVNRT) and atrioventricular reentry tachycardia (AVRT) lack sensitivity and specificity for

92 rial fibrillation, atrial flutter, or atrial tachycardia) between 91 and 365 days after catheter abla

93 chyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or a

94 composite end point, defined as ventricular tachycardia, bradycardia requiring device implantation,

95 ir symptoms; others (monomorphic ventricular tachycardia, Brugada syndrome, torsades de pointes) may

96 We proved the participation of AP in tachycardia by delivering His-synchronous premature vent

97 Atrioventricular nodal reentrant tachycardia can complicate the course of patients with C

98 he catecholaminergic polymorphic ventricular tachycardia-causing N53I substitution, which resides in

99 wallows trigger rapid, robust, and patterned tachycardia conserved across wake, sleep, and arousal st

100 Ivabradine-sensitive atrial tachycardia constitutes 64% of incessant FAT in patients

101 No supraventricular tachycardias converted to VT or ventricular fibrillation

102 ), catecholaminergic polymorphic ventricular tachycardia (CPVT) (n = 9 [8%]), arrhythmogenic right ve

103 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition of abnormal heart rhyt

104 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal genetic arrhy

105 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress-induced cardiac channelop

106 nt catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading cause of sudden death in a

107 of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have ident

108 Catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited cardiac arrhythmia char

109 ng catecholaminergic polymorphic ventricular tachycardia (CPVT).

110 ia catecholaminergic polymorphic ventricular tachycardia (CPVT).

111 th catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in resuscitated patients aft

112 thmic disease (catecholaminergic ventricular tachycardia; CPVT).

113 ablation, postpacing intervals shorter than tachycardia cycle length (difference between postpacing

114 e dimensions of the reentrant VT circuit and tachycardia cycle length (TCL) has not been examined in

115 (difference between postpacing interval and tachycardia cycle length [dPPI] <0 ms) remain of unknown

116 nated electrograms (117+/-18 ms; 44+/-13% of tachycardia cycle length) within the carousel interrupte

117 rams along the carousel encompassed the full tachycardia cycle length, and surrounding activation mov

118 rse was complicated by arterial hypotension, tachycardia, decreasing haemoglobin, increasing acute ph

119 markers of shock, recurrence of ventricular tachycardia, duration of mechanical ventilation, major b

120 ocardial infarction, spontaneous ventricular tachycardia episodes (n = 3) were preceded by significan

121 ocardial infarction, spontaneous ventricular tachycardia episodes (n = 4) were preceded by significan

122 Incessant focal atrial tachycardia (FAT), if untreated, can lead to ventricular

123 orsades de pointe or polymorphic ventricular tachycardia/fibrillation (6% [sustained 3%, nonsustained

124 ]) included presenting rhythm of ventricular tachycardia/fibrillation and pulseless electrical activi

125 end point of cardiac arrest from ventricular tachycardia/fibrillation or bradyarrhythmias such as atr

126 by restricting witnessed SCDs to ventricular tachycardia/fibrillation or nonpulseless electrical acti

127 If only ventricular tachycardia/fibrillation witnessed cases (n=48) were cla

128 Susceptibility to VT/VF (ventricular tachycardia/fibrillation) is difficult to predict in pat

129 ate device therapies terminating ventricular tachycardia/fibrillation.

130 rimary outcome was freedom from AF or atrial tachycardia for longer than 30 seconds after a single pr

131 ctional ventricular tachycardia, ventricular tachycardia, frequent ventricular ectopy, and/or bigemin

132 for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardiac deaths.

133 rdioverter-defibrillator treated ventricular tachycardia >250 beats per minute) in follow-up was asse

134 d ventricular response; (6) supraventricular tachycardia (>15 beats).

135 3) ventricular fibrillation; (4) ventricular tachycardia (>15 beats); (5) atrial fibrillation with ra

136 opathy presenting with recurrent ventricular tachycardia, >10% increase in RV endocardial surface are

137 4 patients with infarct-related ventricular tachycardia had unsuccessful response to radiofrequency

138 the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conduct

139 n times than healthy participants because of tachycardia; however, stroke volume, LV internal diamete

140 h the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administra

141 in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35 to 1.42; p < 0.0001)

142 ypotension (HR: 1.87; 95% CI: 1.02 to 3.43), tachycardia (HR: 2.38; 95% CI: 1.05 to 5.43), and LVEF <

143 noxious pollutants evoke sympathoexcitation (tachycardia, hypertension) in cardiovascular disease pat

144 data based on the presence of hypotension or tachycardia, hypoperfusion, deterioration, and refractor

145 ovascular (CV) manifestations of CRS include tachycardia, hypotension, troponin elevation, reduced le

146 nting arrhythmia was intra-atrial re-entrant tachycardia (IART) (61.6%), followed by atrial fibrillat

147 trial fibrillation, nonsustained ventricular tachycardia, implantable cardiac defibrillator discharge

148 nds (age 15.3 +/- 1.9 years) and ventricular tachycardia in 10 (age 16.6 +/- 2.7 years), 6 probands,

149 andard therapy for treating supraventricular tachycardia in children and adults without transplantati

150 AITC-evoked tachycardia in decerebrate SH rats was abolished by vago

151 length) within the carousel interrupted the tachycardia in every LR case.

152 The initiation of polymorphic ventricular tachycardia in long QT syndrome type 2 (LQT2) has been a

153 VT study (Preventive Ablation of Ventricular Tachycardia in Patients With Myocardial Infarction) was

154 induce transient post-transplant ventricular tachycardia in recent large animal model transplantation

155 cin can cause rapid, polymorphic ventricular tachycardia in the absence of QT prolongation, indicatin

156 ng with left bundle branch block ventricular tachycardia in the setting of arrhythmogenic RV cardiomy

157 t inform ablation strategies for ventricular tachycardia in these diseases.

158 reduced adrenergically mediated ventricular tachycardia in treated mice, (3) reverted ultrastructura

159 pecific pain, headache, hypotension/syncope, tachycardia (including postural orthostatic tachycardia

160 Arousal duration and tachycardia increased in parallel as a function of swall

161 Tachycardiomyopathy or tachycardia-induced cardiomyopathy (TCM) has been known

162 o ventricular dysfunction and heart failure (tachycardia-induced cardiomyopathy).

163 repolarization heterogeneity and ventricular tachycardia inducibility in perfused hearts.

164 ncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE.

165 Atrioventricular reentrant tachycardia is common in children.

166 Tachycardia is common in septic shock, but many patients

167 ategy for ablation of scar-based ventricular tachycardia is delivering multiple lesions in a linear p

168 mus/diastolic channel leading to ventricular tachycardia is unclear.

169 Yet, in inappropriate sinus tachycardia (IST), postural tachycardia syndrome (POTS),

170 ted ventricular fibrillation and ventricular tachycardia (lasting >/=30 seconds or recurrent symptoma

171 Left posterior fascicular ventricular tachycardia (LPF-VT) is frequently misdiagnosed as supra

172 days, CHD, vasoactive infusions, ventricular tachycardia, mechanical ventilation, sepsis, pulmonary h

173 he catecholaminergic polymorphic ventricular tachycardia mice studies, or more generally to suppress

174 achycardia, atrioventricular nodal reentrant tachycardia, monomorphic ventricular tachycardia, and Br

175 mechanisms included atrioventricular reentry tachycardia (n=104, 90 patients), atrioventricular nodal

176 r ectopy (n=10, 8 patients), and ventricular tachycardia (n=15, 13 patients).

177 sequent atrial electrogram or terminated the tachycardia (n=3), and by observing an increase in VA in

178 3, 29 patients), twin atrioventricular nodal tachycardia (n=3, 2 patients), macroreentrant atrial tac

179 achycardia (n=59, 56 patients), focal atrial tachycardia (n=33, 25 patients), ventricular ectopy (n=1

180 90 patients), atrioventricular nodal reentry tachycardia (n=33, 29 patients), twin atrioventricular n

181 dia (n=3, 2 patients), macroreentrant atrial tachycardia (n=59, 56 patients), focal atrial tachycardi

182 two patients in the brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients i

183 tic significance of nonsustained ventricular tachycardia (NSVT) in patients with hypertrophic cardiom

184 r tachycardia (VT), nonsustained ventricular tachycardia (NSVT), and Lown's grade >=2 premature ventr

185 rial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickn

186 A reduction in episodes of ventricular tachycardia occurred in all five patients.

187 patients, with a high freedom from AF/atrial tachycardia off antiarrhythmic drugs at long-term follow

188 TAR-guided ablation were free from AF/atrial tachycardia off antiarrhythmic drugs.

189 y evidence), and inducibility of ventricular tachycardia on electrophysiological study (5 studies; n=

190 ndly decreased vulnerability for ventricular tachycardia on programmed right ventricular and burst st

191 Tachycardia onset was temporally matched to glottic addu

192 rate (HR) and is often accompanied by atrial tachycardia or atrioventricular (AV) block.

193 study included 16 patients with ventricular tachycardia or frequent ventricular premature complexes

194 ng catecholaminergic polymorphic ventricular tachycardia or long QT syndrome and sudden cardiac death

195 ing study criteria scheduled for ventricular tachycardia or PVC ablation over a 9-month period.

196 efibrillation for IHCA caused by ventricular tachycardia or ventricular fibrillation was associated w

197 ts with IHCA caused by pulseless ventricular tachycardia or ventricular fibrillation were stratified

198 mias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).

199 patients with an IHCA caused by ventricular tachycardia or ventricular fibrillation, the rate of 1-y

200 successful conversion of induced ventricular tachycardia or ventricular fibrillation.

201 AVRT was predicted when late PHCs perturbed tachycardia or when earlier PHCs led to atrial advanceme

202 rdioverter-defibrillator treated ventricular tachycardia; or aborted SCD), syncope, 24-hour premature

203 ractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest treated with

204 ntricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest who were rand

205 ractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest.

206 period, there were 4 episodes of ventricular tachycardia over the next 46 patient-months, for a reduc

207 sociated with cardiac arrest and ventricular tachycardia (p = 0.02) and prevalence of PKP2 variants (

208 d number and frequency of ICD shocks or anti-tachycardia pacing therapy.

209 ation to active shooting was associated with tachycardia, perigenual anterior cingulate cortex (pgACC

210 Beta-receptor blockade does not alter the tachycardia phase to low intensity VNS, but can increase

211 injection of AITC evoked bradycardia but no tachycardia/PVCs in conscious SHs, while inhalation and

212 rizations (EADs) and polymorphic ventricular tachycardias (PVTs).

213 Tachycardia recurrence was observed in 54% of the patien

214 Long-term outcome with regard to tachycardia recurrence was worse in patients with comple

215 of the arrhythmic focus without ventricular tachycardia recurrence.

216 safe therapies for scar-related ventricular tachycardias requires a detailed understanding of the me

217 Notably, recurrent monomorphic ventricular tachycardia requiring >/=2 implantable cardioverter-defi

218 ricular ectopy, and nonsustained ventricular tachycardia, respectively.

219 on of gap junctions and promotes ventricular tachycardia, showing the functional significance of FXR1

220 trial fibrillation, general supraventricular tachycardia, sinus bradycardia and sinus rhythm includin

221 CC causes a unique ventricular tachycardia substrate concentrated to the basal lateral

222 l and full thickness ablation of ventricular tachycardia substrate that is not accessible with curren

223 Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac

224 ppropriate sinus tachycardia (IST), postural tachycardia syndrome (POTS), and vasovagal syncope (VVS)

225 into orthostatic hypotension (OH), postural tachycardia syndrome (POTS), or normal HUT groups.

226 Postural orthostatic tachycardia syndrome (POTS), the most common form of ort

227 tachycardia (including postural orthostatic tachycardia syndrome), and malaise/fatigue (including ch

228 nd catecholaminergic polymorphic ventricular tachycardia syndromes) should also be considered cardiom

229 ances in the ability to identify ventricular tachycardia termination sites through high-density mappi

230 ctrocardiographic imaging during ventricular tachycardia that was induced by means of an implantable

231 Among the 73 supraventricular tachycardias, the test accurately predicted AVRT (n=29)

232 antable cardioverter defibrillator (ICD) had tachycardia therapies disabled during the MRI.

233 In idiopathic ventricular tachycardia, there was an increase in incidence rate wit

234 otein (CRP), D-dimer, and fibrinogen levels; tachycardia; thrombocytosis; leukocytosis; fever; leg ed

235 ration of sinus rhythm or suppression of the tachycardia to <100 beats per minute without termination

236 tionship of atrioventricular nodal reentrant tachycardia to congenital heart disease (CHD) and the ou

237 , atrioventricular nodal reentry, and atrial tachycardia, treated with conventional ablation (non-AFN

238 ients with high-risk, refractory ventricular tachycardia underwent treatment.

239 agnosis, documented nonsustained ventricular tachycardia, unexplained syncope, septal diameter z-scor

240 pneumonia, pneumonia aspiration, ventricular tachycardia, upper gastrointestinal hemorrhage, anaphyla

241 R67Q(+/-) mice had bidirectional ventricular tachycardia, ventricular tachycardia, frequent ventricul

242 ) sudden cardiac death/sustained ventricular tachycardia/ventricular fibrillation (SCD/VT/VF).

243 therapy but permits therapy for ventricular tachycardia/ventricular fibrillation (VF).

244 requent ectopy to pacing-induced ventricular tachycardia/ventricular fibrillation (VT/VF).

245 Patients with repetitive ventricular tachycardia/ventricular fibrillation episodes alternatin

246 es or prevents the recurrence of ventricular tachycardia/ventricular fibrillation in such patients.

247 imary end point of time to first ventricular tachycardia/ventricular fibrillation recurrence.

248 priate interventions terminating ventricular tachycardia/ventricular fibrillation.

249 the time to first recurrence of ventricular tachycardia/ventricular fibrillation.

250 gment elevation MI, and 8.9% had ventricular tachycardia/ventricular fibrillation.

251 ntricular fibrillation/pulseless ventricular tachycardia (VF/pVT).

252 Multiple swallows increase the magnitude of tachycardia via temporal summation, and blood pressure i

253 ne to reentry is needed to guide ventricular tachycardia (VT) ablation.

254 ents with myocarditis undergoing ventricular tachycardia (VT) ablation.

255 he GMC in creating substrate and ventricular tachycardia (VT) activation maps during VT ablation proc

256 y of Fallot die prematurely from ventricular tachycardia (VT) and sudden cardiac death.

257 H) ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest is unknown.

258 s of the 3-dimensional nature of ventricular tachycardia (VT) circuits.

259 Postinfarction ventricular tachycardia (VT) generally involves myocardial fibers su

260 Ablation of postinfarction ventricular tachycardia (VT) has been shown to reduce VT recurrence

261 rious strategies for ablation of ventricular tachycardia (VT) have been described, but their impact o

262 ding radiofrequency ablation for ventricular tachycardia (VT) in patients with cardiogenic shock and

263 Background Catheter ablation of ventricular tachycardia (VT) in structural heart disease is challeng

264 mias during catheter ablation of ventricular tachycardia (VT) in structurally abnormal hearts remains

265 Catheter ablation of ventricular tachycardia (VT) is being increasingly performed; yet, t

266 schemic cardiomyopathy (ICM) and ventricular tachycardia (VT) is important for understanding the pati

267 LP) abolition and postprocedural ventricular tachycardia (VT) noninducibility is known to be the desi

268 end point was the first event of ventricular tachycardia (VT) or fibrillation (VF).

269 ablation procedure for sustained ventricular tachycardia (VT) or nonsustained VA with associated left

270 Ventricular tachycardia (VT) radiofrequency ablation has been associ

271 Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of VT in patient

272 al and functional changes in the ventricular tachycardia (VT) substrate.

273 In contrast to ventricular tachycardia (VT) that occurs in the setting of a structu

274 vasive cardiac radioablation for ventricular tachycardia (VT) using stereotactic body radiation thera

275 Polymorphic ventricular tachycardia (VT) without QT prolongation is well describ

276 To facilitate ablation of ventricular tachycardia (VT), an automated localization system to id

277 luding ventricular fibrillation, ventricular tachycardia (VT), nonsustained ventricular tachycardia (

278 In infarct-related ventricular tachycardia (VT), the circuit often corresponds to a loc

279 ed in electroanatomic mapping in ventricular tachycardia (VT).

280 ular pathological remodeling and ventricular tachycardia (VT).

281 susceptibility to develop acute ventricular tachycardia (VT).

282 a novel treatment for refractory ventricular tachycardia (VT).

283 : 63 (group 1) having documented ventricular tachycardia (VT)/ventricular fibrillation (VF) and Bruga

284 ythmic substrate for postinfarct ventricular tachycardias (VT) identifiable on contrast-enhanced comp

285 topy >=5%), most often moderate (ventricular tachycardia [VT]; 120 to 179 beats/min) in 27%, and rare

286 Fast ventricular tachycardias (VTs) have historically been attributed to

287 xpanded the spectrum of mappable ventricular tachycardias (VTs).

288 thways because the septal VA interval during tachycardia was <70 ms in 3, 1 had spontaneous atriovent

289 The mean atrial rate during tachycardia was 170+/-21 beats per minute, and the mean

290 of catecholaminergic polymorphic ventricular tachycardia was determined for all RYR2-positive individ

291 Recurrence of tachycardia was more likely in patients with complex sur

292 cardia, atrial fibrillation, and ventricular tachycardia were found to be the most common or life-thr

293 ients with nodofascicular or nodoventricular tachycardia were studied.

294 rial fibrillation, atrial flutter, or atrial tachycardia while not receiving antiarrhythmic medicatio

295 frequently misdiagnosed as supraventricular tachycardia with aberrant right bundle branch block (RBB

296 TC in conscious SH rats evoked complex brady-tachycardia with both AV block and premature ventricular

297 f right ventricular scar-related ventricular tachycardia with computed tomographic image integration,

298 ome characterized by polymorphic ventricular tachycardia with physical or emotional stress, for which

299 sensitive bradycardia and atenolol-sensitive tachycardia with premature ventricular contractions (PVC

300 e response was defined as the termination of tachycardia with the restoration of sinus rhythm or supp